Individualizing
Extended
Endocrine
Therapy
Decisions
Cancer
Index
Ten Years Of Endocrine Therapy: Is It Right For Your Patients?
Nearly 95% Of Women With Early-Stage, Hormone Receptor–Positive (HR+) Breast Cancer Do Not Benefit From Extended Endocrine Therapy1-6
Trials consistently demonstrate that only 3-5% of women benefit from extended endocrine therapy1-6, supporting the strong need for individualized patient selection rather than broad use of prolonged treatment.
Adjuvant Endocrine Therapy Extension: 5 vs 10 Years1-5
* Based on disease-free survival or cumulative risk of recurrence rates as reported in the primary publications (note that the definitions of disease-free were not identical across trials)
Genomic Classifiers That Predict Risk Of Late Recurrence And/Or Benefit From Extended Endocrine Therapy May Help To Further Individualize The Recommendation For Extended Aromatase Inhibitor Therapy.”5
- Eleftherios P. Mamounas, MD
While A Small Percentage Of Early-Stage, HR+ Patients Benefit From Extended Endocrine Treatment, Nearly 95% Do Not.1-6
100% Of Women Deserve To Know
What Is Right For Them.
Learn how Breast Cancer Index® can help determine which of your patients are among the women who are likely to benefit from extended endocrine therapy.
The Predictive Power of Breast Cancer IndexReferences: 1. Davies C, et al. Lancet Oncol. 2013;381: 805-816. 2. Gray R et al. J Clin Oncol 2013; 31: (suppl; abstr 5). 3. Jakesz R, et al. J Natl Cancer Inst. 2007;99: 1845-1853. 4. Goss PE, et al. J Natl Cancer Inst. 2005;97: 262-1271. 5. Mamounas EP et al. NSABP B-42. GS4-01. SABCS 2019. Dec 12, 2019. 6. Goss PE et al. N Engl J Med. 2016; 375:209-219.
Back To All
